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Background: Patients with hereditary haemochromatosis (HH) are usually homozygous for the C282Y
mutation in the HFE gene. They have variable expression of iron overload and present with a variety of
complications, including liver disease, diabetes, arthropathy, fatigue, and cardiomyopathy. The
mitochondrial 16189 variant is associated with diabetes, dilated cardiomyopathy, and low body fat at
birth, and might contribute to genetic predisposition in further multifactorial disorders. The objective of this
study was to determine the frequency of the 16189 variant in a range of patients with haemochromatosis,
who had mutations in the HFE gene.
Methods: Blood DNA was analysed for the presence of the 16189 variant in British, French, and
Australian C282Y homozygotes and controls, with known iron status, and in birth cohorts.
Results: The frequency of the mitochondrial 16189 variant was found to be elevated in individuals with
haemochromatosis who were homozygous for the C282Y allele, compared with population controls and
with C282Y homozygotes who were asymptomatic (42/292 (14.4%); 102/1186 (8.6%) (p = 0.003);
and 2/64 (3.1%) (p = 0.023), respectively).
Conclusions: Iron loading in C282Y homozygotes with HH was exacerbated by the presence of the
mitochondrial 16189 variant.
INTRODUCTION
Hereditary haemochromatosis (HH) (OMIM 235200) is an
autosomal recessive disorder of iron metabolism. The HH
associated mutation, C282Y, in the HFE gene, is common in
Northern Europeans, among whom approximately 1/300 are
C282Y homozygotes (Genbank accession U60319)1). The
C282Y mutation disrupts formation of the disulphide bond
in the a3 domain of the HFE protein, thus preventing its
normal association with b2-microglobulin (b2M).
2 This
dramatically reduces cell surface expression of the complex.3 4
The HFE/b2M complex normally interacts with the transfer-
rin receptor, which enables the cell to regulate iron uptake.5–9
In persons with haemochromatosis, iron eventually accumu-
lates in parenchymal cells, causing a number of complica-
tions such as chronic fatigue, arthritis, diabetes, heart
disease, skin pigmentation, and liver fibrosis and cirrhosis.10
Over 90% of patients with HH in the UK are homozygous
for the C282Y mutation.11 In France and Australia, between
72% and 100% of people with HH are C282Y homozygotes.12–14
A small proportion of iron loaded patients are compound
heterozygotes for C282Y and a much milder mutation, H63D.2
Not all C282Y homozygotes become iron loaded.15 Many
studies demonstrate incomplete penetrance in HH,16–19 and
these suggest that most people who are C282Y homozygotes
will have increased transferrin saturation, but only some will
develop an increased ferritin concentration. A smaller
proportion will have clinical signs of the disease.
Modifier genes have been shown to influence penetrance
in a number of conditions.20 Such genes can enhance or
reduce the phenotypic expression in many diseases. Dietary
and environmental factors have been shown to influence
haemochromatosis, and studies investigating penetrance of
haemochromatosis in mouse models have demonstrated that
heritable factors influence iron homeostasis.21–24 We have
recently described digenic inheritance of juvenile haemo-
chromatosis in an individual with the C282Y mutation in
HFE and the Met50del IVS2+1(-G) mutation in the hepcidin
gene.25
Iron deposition and/or loading is associated with impaired
mitochondrial function in subjects with a variety of
diseases.26–29 Chronic fatigue is a typical symptom of both
HH30 and mitochondrial disease.31 32 Diabetes is asso-
ciated with HH; the presence of a mitochondrial DNA
(mtDNA) variant at position 16189 appears to be a risk
factor for developing type 2 diabetes.33–35 The 16189 variant
is situated in the hypervariable, non-coding region of
the mitochondrial genome (mtDNA), HV-1, within the
D-loop. The variant is characterised by a TRC substitution
at position 16189, which produces a highly variable poly
C tract.34 It is therefore frequently accompanied by
heteroplasmic length variation. The 16189 variant is com-
mon in some Pacific populations, with a frequency of
96%,36 and diabetes has become almost epidemic in these
populations as they are increasingly exposed to Western
lifestyles.
Some aspects of mitochondrial function may be important
for oxygen sensing,37–39 which in turn influences iron loading.
It therefore seemed appropriate to investigate the role of
mitochondria in relation to HH and iron homeostasis. We
have begun by examining the frequency of the mtDNA 16189
variant in several groups of people with conditions involving
mutations in the HFE gene.
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METHODS
Study subjects
A total of 1585 subjects of UK, French, and Australian origin
were tested for the presence of the 16189 variant in the D-
loop of mtDNA. These subjects fell into five groups, two of
which had iron overload (groups 1 and 2, a total of 335
patients) and three of which did not (groups 3–5).
Group 1 comprised C282Y homozygotes with haemochro-
matosis, who had a transferrin saturation of more than 40%
and a serum ferritin concentration of more than 300 mg/l, in
the absence of any other cause of iron loading. The age range
was from 29 to 89 years, (mean 49.5 years, standard
deviation (SD) 13.9). Two subjects had type 1 diabetes (b
cell destruction), and 10 had type 2 diabetes. The majority of
these participants had completed iron depletion treatment
and so had had more than 5 g of iron removed by
quantitative phlebotomy.
Group 2 comprised subjects with intermediate iron
loading. These were French patients with haemochromatosis,
who were compound heterozygotes for the H63D and C282Y
mutations in HFE. The age range was from 27 to 64 years
(mean 39 years, SD 7.5). Five participants had type 2 diabetes
and two had diabetes that was neither type 1 nor type 2. The
iron overload in this group was less severe than in group 1,
and less than 4 g of iron had been removed by quantitative
phlebotomy.
Group 3 included C282Y homozygotes without haemo-
chromatosis; their serum ferritin concentrations fell within
the normal range. These samples were either identified as
part of an anonymous blood donor study in South Wales17 or
as part of a free national health check in France.19 The age
range of the samples was from 22 to70 years (mean 40 years,
SD 1.5). No one in this group was known to have diabetes.
Group 4 comprised two subgroups with normal serum
ferritin—that is, random blood donors and H63D homo-
zygotes. The 89 random blood donors were from South Wales
and had normal iron indices.17 The genotypes in this sub-
group included HH/CC (57), HD/CC (18), HH/CY (11), HD/CY
(2), and DD/CC (1), demonstrating allele frequencies of 6.2%
and 11.2% for C282Y and H63D, respectively. The second
subgroup comprised H63D homozygotes, 26 of whom were
picked up as part of a free national health check in France
and 165 from the Welsh blood donor survey .17 40 Their ages
ranged from 27 to 91 years (mean 40.3 years, SD 15.7).
The birth cohorts (group 5) were all of North West
European ancestry, and were chosen with no recruitment
bias with respect to iron stores. We involved, as UK
Caucasian controls, a birth cohort from the Avon area that
had previously been typed for the 16189 variant. The French
birth cohort from Amiens was typed for HFE mutations, but
the British and Australian birth cohorts were not. The HFE
allele frequencies (5.0% for C282Y and 18.0% for H63D) in
the French birth cohort did not differ from those in a healthy
adult control population from the same area.
All patient samples were maternally unrelated and were
tested for the C282Y and H63D mutations.41–43 Our study
forms part of a larger study investigating phenotype/genotype
relationships in haemochromatosis. Samples were collected
locally under procedures approved by the appropriate ethical
committee.
Detection of the 16189 polymorphism
DNA was extracted using standard methods. Polymerase
chain reaction (PCR) amplification of the D-loop of mtDNA
was carried out as previously described.44 Digestion of PCR
products with MnlI took place at 37 C˚ for more than four
hours, according to the manufacturer’s specifications (New
England Biolabs, Beverly, MA). Digested products were
resolved by electrophoresis in 2% agarose gels. In the wild
type sequence, there was a restriction site at position 16189,
giving a major fragment of 323bp. In the mutant allele, the
Mnl I site at 16189 was absent, giving a major fragment of
358bp.
Sequence analysis
Sequence analysis, using an ABI 377 automated sequencer
(Applied Biosystems, Warrington, UK), was carried out on
samples that were positive for the 16189 variant. A standard
protocol was followed using ABI Big Dye terminators. A
Strata PrepH purification kit was employed to purify the first
round PCR amplification products used as template. Because
of possible heteroplasmic length variation, all samples
lacking the MnlI site were sequenced in both directions.
The sequences were compared with a reference sequence, and
assigned to particular mtDNA haplogroups on the basis of
diagnostic motifs.45 46
Statistical analysis
Statistical analysis was performed using the SPSS package.
Logistic regression was necessary to fit a proportion
parameter for each country and each group at the same
time. One tailed significance was used because the null
hypothesis was that the 16189 variant would be more
frequent in affected than unaffected individuals, consistent
with a role in exacerbating the phenotype.
RESULTS
The results are shown in tables 1 and 2. The frequency of the
16189 variant was highest, at 14.4% (42/292), in those C282Y
homozygotes with haemochromatosis (group 1). This was
significantly higher than for the birth cohort controls, where
the frequency was 8.6% (78/906, p = 0.029) (group 5). The
lowest frequency of 3.1% (2/64) was observed for group 3,
C282Y homozygotes who did not have haemochromatosis.
This was significantly lower than the frequency in individuals
with haemochromatosis who were C282Y homozygotes (p =
0.023) (group 1 v group 3).
The other group expressing symptoms of iron overload,
group 2 (compound heterozygotes with HH), also had higher
16189 frequencies (11.6%) than the birth cohort control
group, but this difference was not significant. There was no
significant difference between groups 1 and 2.
Table 1 Comparison of HFE genotype with the
frequency of the 16189 variant in subjects with
haemochromatosis and healthy controls
Subjects
British
(%)
French
(%)
Australian
(%) Total (%) Group
C282Y
homozygotes
with increased
iron
22/157
(14.0)
15/112
(13.4)
5/23
(21.7)
42/292
(14.4)
1
Patients with
intermediate
iron
5/43
(11.6)
5/43
(11.6)
2
C282Y
homozygotes
with normal
iron
1/43
(2.3)
1/21
(4.8)
2/64
(3.1)
3
Controls with
normal iron
23/254
(9.1)
1/26
(3.7)
24/280
(8.6)
4
Birth cohort 48/545
(8.8)
19/204
(9.3)
*11/157
(7.0)
78/906
(8.6)
5
Total 94/999
(9.4)
41/406
(10.1)
16/180
(8.8)
151/1585
(9.52)
*There were, in addition, three participants with both the 16189 variant
and heteroplasmy for a C to T transition at bp 16193. The p values are
barely altered when these are included.
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The H63D allele is much more common than the C282Y
allele in European populations, having allele frequencies
between 10 and 20%.41 Up to 5% of persons with haemo-
chromatosis are compound heterozygotes, and less than 1%
of persons with iron overload in the UK are H63D
homozygotes.11 We compared the 191 H63D homozygotes in
group 4 (age range from 27 to 91 years) with the birth cohort
(group 5). The overall frequency of the 16189 variant in the
H63D homozygotes (group 4) was 9.4% (18/191). This was
not significantly different from the birth cohort (group 5)
(8.6%).
The British component of group 5 was a birth cohort from
the Avon area in which the 16189 variant had previously
been found to be present in 8.8% (48/545) of samples,47
consistent with other European Caucasian studies.4 49 The
frequency of the 16189 variant was slightly lower in the 89
blood donors from South Wales (6.7%) than in the birth
cohorts (8.6%).
In table 2, the odds ratios for the presence of the 16189
variant were significantly greater for the British participants
who were C282Y homozygotes with iron loading than for
those with normal ferritin concentrations (p = 0.025).
Logistic regression was used to calculate the odds ratios for
comparisons between the totals adjusting for the countries,
and gave odds ratios of 2.05 and 1.77 for the presence of the
variant in subjects who were C282Y homozygotes with iron
loading, compared with unloaded individuals and birth
cohorts, respectively (see tables 1 and 2). Logistic regression
of the proportion of participants who were positive for the
16189 variant on iron loading (group 1 v group 2 v group 3)
for the UK and France was carried out. Adjusting for country,
this showed that there was a significant (p = 0.03)
downward linear trend in the log of the odds ratios from
the French and British patients with increased to inter-
mediate to normal iron loading (with multiplicative steps in
odds ratios of 0.58 downwards, or 1.735 upwards from 3 to 2
to 1).
DISCUSSION
In this study we demonstrated an increased frequency of the
16189 variant in C282Y homozygotes with haemochromatosis
compared with individuals with the same HFE genotype who
did not show signs of iron overload (14.4% and 3.1%,
respectively, compared with 8.4% of controls). Although we
did not obtain our baseline frequency for the 16189 variant
using matched controls, mtDNA haplotyping was able to
exclude the possibility of a spurious association due to the
known C282Y founder effect. MtDNA analysis demonstrated
that the 16189 variant had arisen on several different
mitochondrial haplogroups (table 3). These data were
consistent with other studies in which H and U are the
commonest European haplotypes.45 46 Moreover, the excess of
individuals with the 16189 variant among those with
haemochromatosis was not due to a single mitochondrial
haplotype. Together, these results suggest that the associa-
tion we demonstrated was due to an effect of the 16189
variant itself, rather than of another pathogenic mtDNA
mutation when cosegregating with it.
Table 3 shows a comparison of the mitochondrial DNA
haplogroup associated with the 16189 variant in all the
different groups. Haplogroup B is derived from Asia, Oceania,
and native American populations, whereas the remaining
haplogroups originate mainly from Europe, North Africa, and
Western Asian Caucasians. Those in groups 1 and 2 have
haemochromatosis and intermediate iron overload, respec-
tively. Group 3 includes asymptomatic C282Y homozygotes,
and group 4 consists of asymptomatic H63D homozygotes
and healthy blood donors. Group 5 comprises the birth cohort
controls.
We postulate that, in haemochromatosis, mitochondrial
function might influence iron loading. There was a clear
association of the 16189 variant with iron loading in the
presence of the C282Y mutation. Diabetes and chronic fatigue
are features of both HH and mitochondrial disease. Patients
with both C282Y and the 16189 variant may be subject to
these complications. Further studies are needed to confirm
our hypothesis that the 16189 variant influences iron loading
in C282Y homozygotes, and to a lesser extent in C282Y
heterozygotes with disease.
Some aspects of mitochondrial function may be important
in oxygen sensing,37–39 which is central to iron homeostasis.
Oxygen levels contribute to transcriptional and translational
control of several genes involved in iron homeostasis such as
transferrin, transferrin receptor, ferritin, ceruloplasmin, and
heme-oxygenase 1. Hypoxia inducible factor (HIF-1) is a key
regulator in this process.50–54 Hepcidin levels are reduced by
hypoxia55 and may be inappropriately low in untreated
patients with haemochromatosis.56 Mutations in hepcidin
can result in juvenile haemochromatosis,57 and may play a
key role in modifying the severity of haemochromatosis in
C282Y heterozygotes and homozygotes.25 Hepcidin is a type II
acute phase protein.58 The effects of impaired mitochondrial
function and of the presence of the 16189 variant on hepcidin
levels and thence on iron loading are currently unknown.
Involvement of mitochondria in iron balance, perhaps
because of a role in iron sensing, would be biologically
plausible: iron is required by mitochondria for the synthesis
of cytosolic proteins required for the normal assembly of the
electron transport complexes.
We suggest that the 16189 variant produces a subtle defect
in mitochondrial function. It lies close to conserved
sequences that contain the origin of mtDNA replication of
the heavy strand (OH), as well as both promoters. Hence it is
Table 2 Odds ratios, 95% (one sided) confidence
intervals, and one sided p values for the presence of the
16189 variant in patients homozygous for the C282Y
mutation and iron loading (group 1), compared with
those with normal serum ferritin concentrations (groups 3
and 4) and the birth cohort controls (group 5)
Group British Total
Odds loaded (group 1) v
unloaded (groups 3 and 4)
1.85 (1.11–‘)
p = 0.025
2.05 (1.29–‘)
p = 0.006
Odds loaded (group 1) v
birth cohort (group 5)
1.69 (1.07–‘]
p = 0.029
1.77 (1.26–‘)
p = 0.003
Table 3 Comparison* of haplogroups within each subject group
Group B H I J K T U V W X Unknown
1 5.3 (2) 42.1 (16) 0 2.6 (1) 0 5.3 (2) 34.2 (13) 0 0 7.9 (3) 2.6 (1)
2 0 0 0 0 0 0 60 (3) 0 20 (1) 20 (1) 0
3, 4, 5 0 36.7 (18) 10.2 (5) 2.0 (1) 2.0 (1) 8.2 (4) 22.5 (11) 2.0 (1) 0 12.2 (6) 4.1 (2)
*Results are expressed as %, with the number of samples sequenced in brackets.
B to X, the haplogroups associated with the 16189 variant.
8 Livesey, Wimhurst, Carter, et al
www.jmedgenet.com
possible that this region of mtDNA is involved in regulating
mtDNA copy number.59 Previous investigators have used
organello dimethyl sulphate footprinting assays to demon-
strate that proteins bind to sites in this region of mtDNA.60
Preliminary data suggest that the 16189 variant affects cell
function,61 and that in some tissues the presence of the 16189
variant may result in reduced mitochondrial copy number
(J Poulton, unpublished data). This might impair a cell’s
maximum rate of oxidative phosphorylation.
The combination of the 16189 variant and excess iron due
to the presence of C282Y HFE alleles may be cumulative in
causing disease in some haemochromatosis patients. Too
much or too little iron can induce mitochondrial DNA
damage, oxidative stress, and mitochondrial dysfunction.62
Our results suggest that iron loading in these patients is
exacerbated by the presence of the 16189 variant, which may
confer a subtle reduction in mitochondrial function.
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A
ll patients with Leber’s hereditary optic neuropathy should be screened for cardiac
abnormalities, according to a team of investigators from London who screened 24
consecutive patients and found that eight had cardiac symptoms, 14 had ECG
abnormalities and five had myocardial hypertrophy. The five patients with myocardial
hypertrophy, defined as a left ventricular wall thickness of 15mm or more on two
dimensional echocardiography, were all from the same family, and carried the same
mitochondrial DNA point mutation, known as 3460. Patients with the other two
mitochondrial DNA mutations associated with Leber’s hereditary optic neuropathy (11778
and 14484) had no myocardial hypertrophy. Nor did six other members of the family
carrying the 3460 mutation. Experts have long suspected that Leber’s hereditary optic
neuropathy could affect the heart, and at least one previous study suggests an association
with left ventricular pre excitation. This latest study is probably the first describing
hypertrophic cardiomyopathy in patients with the disease.
The three mitochondrial DNA mutations 3460, 11778, and 14484 account for 90% of
Leber’s hereditary optic neuropathy. All alter the encoding of complex 1, a major protein
complex in the mitochondrial oxidative phosphorylation system. It’s unclear exactly why
patients with the 3460 mutation seem more prone to hypertrophic cardiomyopathy than
patients with the other mutations, although the three mutations affect different protein
subunits in complex 1. Mutation 3460, for example, alters the ND1 subunit which causes a
30–35% decrease in ATP synthesis. Mutation 11778 alters the ND4 subunit, and mutation
14484 alters the ND6 subunit. More research is needed to investigate the impact of these
different alterations on the myocardium.
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